Advertisement
Review Article| Volume 16, ISSUE 1, P87-96, March 2023

Download started.

Ok

Preoperative, Intraoperative, and Postoperative Parathyroid Pathology

Clinical Pathologic Collaboration for Optimal Patient Management
Published:December 09, 2022DOI:https://doi.org/10.1016/j.path.2022.10.001

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgical Pathology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bilezikian J.P.
        • Bandeira L.
        • Khan A.
        • et al.
        Hyperparathyroidism.
        Lancet. 2018; 391 (ISSN 0140-6736): 168-178
        • Barczyński M.
        • Bränström R.
        • Dionigi G.
        • et al.
        Sporadic multiple parathyroid gland disease--a consensus report of the European Society of Endocrine Surgeons (ESES).
        Langenbeck's Arch Surg. 2015; 400: 887-905
        • Insogna K.L.
        Primary Hyperparathyroidism.
        N Engl J Med. 2018; 379: 1050-1059
        • Galani A.
        • Morandi R.
        • Dimko M.
        • et al.
        Atypical parathyroid adenoma: clinical and anatomical pathologic features.
        World J Surg Oncol. 2021; 19: 19
        • Walker M.D.
        • Silverberg S.J.
        Primary hyperparathyroidism.
        Nat Rev Endocrinol. 2018; 14: 115-125
        • Pappachan J.M.
        • Elnaggar M.N.
        • Sodi R.
        • et al.
        Primary hyperparathyroidism: findings from the retrospective evaluation of cases over a 6-year period from a regional UK centre.
        Endocrine. 2018; 62: 174-181
        • Bilezikian J.P.
        • Luisa Brandi M.
        • Eastell R.
        • et al.
        Claudio Marcocci, John T. Potts, Jr, Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop.
        J Clin Endocrinol Metab. 2014; 99: 3561-3569
        • Wilhelm S.M.
        • Wang T.S.
        • Ruan D.T.
        • et al.
        The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism.
        JAMA Surg. 2016; 151: 959-968
        • Elliott D.D.
        • Monroe D.P.
        • Perrier N.D.
        Parathyroid histopathology: is it of any value today?.
        J Am Coll Surg. 2006; 203: 758e65
        • Starr F.L.
        • DeCresce R.
        • Prinz R.A.
        Use of intraoperative parathyroid hormone measurement does not improve success of bilateral neck exploration for hyperparathyroidism.
        Arch Surg. 2001; 136: 536-542
        • Perrier N.D.
        • Ituarte P.
        • Kikuchi S.
        • et al.
        Intraoperative parathyroid aspiration and parathyroid hormone assay as an alternative to frozen section for tissue identification.
        World J Surg. 2000; 24: 1319-1322
        • Cipriani N.A.
        • Glomski K.
        • Sadow P.M.
        Intraoperative assessment of parathyroid pathology in sporadic primary hyperparathyroidism: an institutional experience.
        Hum Pathol. 2022; 123: 40-45
        • McCoy K.L.
        • Yip L.
        • Dhir M.
        • et al.
        Histologic hypercellularity in a biopsied normal parathyroid gland does not correlate with hyperfunction in primary hyperparathyroidism.
        Surgery. 2021; 169: 524-527
        • Castleman B.
        • Mallory T.B.
        The Pathology of the Parathyroid Gland in Hyperparathyroidism: A Study of 25 Cases.
        Am J Pathol. 1935; 11: 1-72
        • Nazikawa H.
        • Rosen P.
        • Lane N.
        • et al.
        Frozen section experience in 3000 cases. Accuracy, limitations, and value in residency training.
        Am J Clin Pathol. 1968; 49: 41-51
      1. Roth SI, Sadow PM, Belsley Johnson N, et al. Parathryoid. In: Mills SE, editor. Histopathology for Pathologists. 4th Edition. Philadelphia, PA: Wolters Kuwer Lippincott Williams & Wilkins. 2012. pp. 1209-1230.

        • Dehner L.P.
        • Rosai J.
        Frozen section examination in surgical pathology: a retrospective study of one year experience, comprising 778 cases.
        Minn Med. 1977; 60: 83-94
        • Mcgarity W.C.
        • Mathews W.H.
        • Fulenwider J.T.
        • et al.
        The surgical management of primary hyperparathyroidism: a personal series.
        Ann Surg. 1981; 193: 794-804
        • Dankawa E.K.
        • Davies J.D.
        Frozen section diagnosis: an audit.
        J Clin Pathol. 1985; 38: 1235-1240
        • Baloch Z.W.
        • LiVolsi V.A.
        Intraoperative assessment of thyroid and parathyroid lesions.
        Semn Diagn Pathol. 2002; 19: 219-226
        • Dewan A.K.
        • Kapadia S.B.
        • Hollenbeack C.S.
        • et al.
        Is routine frozen section necessary for parathyroid surgery?.
        Otolaryngol Head Neck Surg. 2005; 133: 857-862
        • Faquin W.C.
        • Roth S.I.
        Frozen section of thyroid and parathyroid specimens.
        Arch Pathol Lab Med. 2006; 130: 1260
        • Singleton A.O.
        • Allums J.
        Identification of Parathyroid Glands by Toluidine Blue Staining.
        Arch Surg. 1970; 100: 372-375
        • Rosen I.B.
        • Bohnen D.R.
        • Walfish P.G.
        The use of toluidine blue in locating abnormal parathyroid tissue at operation.
        Can Med Assoc J. 1974; 110: 393-396
        • Monchik J.M.
        • Farrugia R.
        • Teplitz C.
        • et al.
        Parathyroid surgery: the role of chief cell intracellular fat staining with osmium carmine in the intraoperative management of patients with primary hyperparathyroidism.
        Surgery. 1983; 94: 877-886
        • Taillefer R.
        • Boucher Y.
        • Potvin C.
        • et al.
        Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study).
        J Nucl Med. 1992; 33: 1801-1807
        • Penner C.R.
        • Thompson L.D.
        Primary parathyroid hyperplasia.
        Ear Nose Throat J. 2003; 82: 363
        • Takahashi F.
        • Denda M.
        • Finch J.L.
        • et al.
        Hyperplasia of the parathyroid gland without secondary hyperparathyroidism.
        Kidney Int. 2002; 61: 1332-1338
        • Guilmette J.
        • Sadow P.M.
        Parathyroid Pathology.
        Surg Pathol Clin. 2019; 12: 1007-1019
        • Erickson L.A.
        • Mete O.
        • Juhlin C.C.
        • et al.
        Overview of the 2022 WHO Classification of Parathyroid Tumors.
        Endocr Pathol. 2022; 33: 64-89
        • Cetani F.
        • Marcocci C.
        • Torregrossa L.
        • et al.
        Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors.
        Endocrine-Related Cancer. 2019; 26 (Retrieved Apr 7, 2022): R441-R464
        • Persson S.
        • Hansson G.
        • Hedman I.
        • et al.
        Primary parathyroid hyperplasia of water-clear cell type. Transformation of water-clear cell type.
        Acta Pathol Microbiol Immunol Scand A. 1986; 94: 391-395
        • Fernandez-Ranvier G.G.
        • Khanafshar E.
        • Jensen K.
        • et al.
        Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis?.
        Cancer. 2007; 110: 255-264
        • Wani S.
        • Hao Z.
        Atypical cystic adenoma of the parathyroid gland: case report and review of the literature.
        Endocr practices. 2005; 11: 389-393
        • Bergenfelz A.
        • Tennvall J.
        • Valdermarsson S.
        • et al.
        Sestamibi versus thallium subtraction scintigraphy in parathyroid localization: a prospective comparative study in patients with predominantly mild primary hyperparathyroidism.
        Surgery. 1997; 121: 601-605
        • Leiker A.J.
        • Yen T.W.
        • Eastwood D.C.
        • et al.
        Factors that influence parathyroid hormone half-life: determining if new intraoperative criteria are needed.
        JAMA Surg. 2013; 148: 602-606
        • Sokoll L.J.
        • Drew H.
        • Udelsman R.
        Intraoperative parathyroid hormone analysis: A study of 200 consecutive cases.
        Clin Chem. 2000 Oct; 46: 1662-1668
        • Calò P.G.
        • Pisano G.
        • Loi G.
        • et al.
        Intraoperative parathyroid hormone assay during focused parathyroidectomy: the importance of 20 minutes measurement.
        BMC Surg. 2013; 13: 36
        • Mak N.T.J.J.
        • Li J.
        • Vasilyeva E.
        • et al.
        Intraoperative parathyroid hormone measurement during parathyroidectomy for treatment of primary hyperparathyroidism: When should you end the operation?.
        Am J Surg. 2020; 219: 785-789
        • Richards M.L.
        • Thompson G.B.
        • Farley D.R.
        • et al.
        An Optimal Algorithm for Intraoperative Parathyroid Hormone Monitoring.
        Arch Surg. 2011; 146: 280-285
        • Iacobone M.
        • Scarpa M.
        • Lumachi F.
        • et al.
        Are frozen sections useful and cost-effective in the era of intraoperative qPTH assays?.
        Surgery. 2005; 138 ([discussion: 1164-5]): 1159-1164
        • Low R.A.
        • Katz A.D.
        Parathyroidectomy via bilateral cervical exploration: a retrospective review of 866 cases.
        Head Neck. 1998; 20: 583-587
        • Quinn A.J.
        • Ryan É.J.
        • Garry S.
        • et al.
        Use of Intraoperative Parathyroid Hormone in Minimally Invasive Parathyroidectomy for Primary Hyperparathyroidism: A Systematic Review and Meta-analysis.
        JAMA Otolaryngol Head Neck Surg. 2021; 147: 135-143
        • Medas F.
        • Cappellacci F.
        • Canu G.L.
        • et al.
        The role of Rapid Intraoperative Parathyroid Hormone (ioPTH) assay in determining outcome of parathyroidectomy in primary hyperparathyroidism: A systematic review and meta-analysis.
        Int J Surg. 2021; 92: 106042
        • Chen H.
        • Pruhs Z.
        • Starling J.R.
        • et al.
        Intraoperative parathyroid hormone testing improves cure rates in patients undergoing minimally invasive parathyroidectomy.
        Surgery. 2005; 138: 583-587
        • Barczynski M.
        • Konturek A.
        • Cichon S.
        • et al.
        Intraoperative parathyroid hormone assay improves outcomes of minimally invasive parathyroidectomy mainly in patients with a presumed solitary parathyroid adenoma and missing concordance of preoperative imaging.
        Clin Endocrinol (Oxf). 2007; 66: 878-885
        • Li J.
        • Vasilyeva E.
        • Hiebert J.
        • et al.
        Limited clinical utility of intraoperative frozen section during parathyroidectomy for treatment of primary hyperparathyroidism.
        Am J Surg. 2019; 217: 893-898
        • Westra W.H.
        • Pritchett D.D.
        • Udelsman R.
        Intraoperative confirmation of parathyroid tissue during parathyroid exploration: a retrospective evaluation of the frozen section.
        Am J Surg Pathol. 1998; 22: 538-544
        • Anton R.C.
        • Wheeler T.M.
        Frozen section of thyroid and parathyroid specimens.
        Arch Pathol Lab Med. 2005; 129: 1575-1584
        • Chan R.K.
        • Ibrahim S.I.
        • Pil P.
        • et al.
        Validation of a Method to Replace Frozen Section During Parathyroid Exploration by Using the Rapid Parathyroid Hormone Assay on Parathyroid Aspirates.
        Arch Surg. 2005; 140: 371-373
        • DeLellis R.
        Parathyroid tumors and related disorders.
        Mod Pathol. 2011; 24: S78-S93
        • Howson P.
        • Kruijff S.
        • Aniss A.
        • et al.
        Oxyphil Cell Parathyroid Adenomas Causing Primary Hyperparathyroidism: a Clinico-Pathological Correlation.
        Endocr Pathol. 2015 Sep; 26: 250-254
        • Bleier B.S.
        • LiVolsi V.A.
        • Chalian A.A.
        • et al.
        Technetium Tc 99m Sestamibi Sensitivity in Oxyphil Cell–Dominant Parathyroid Adenomas.
        Arch Otolaryngol Head Neck Surg. 2006; 132: 779-782
        • Erickson L.A.
        • Jin L.
        • Papotti M.
        • et al.
        Oxyphil Parathyroid Carcinomas.
        The Am J Surg Pathol March. 2002; 26: 344-349
        • Bai S.
        • LiVolsi V.A.
        • Fraker D.L.
        • et al.
        Water-Clear Parathyroid Adenoma: Report of Two Cases and Literature Review.
        Endocr Pathol. 2012; 23: 196-200
        • Juhlin C.C.
        • Nilsson I.L.
        • Falhammar H.
        • et al.
        Institutional characterisation of water clear cell parathyroid adenoma: a rare entity often unrecognised by TC-99m-sestamibi scintigraphy.
        Pathology. 2021; 53: 852-859
        • Schmid K.W.
        • Hittmair A.
        • Ladurner D.
        • et al.
        Chromogranin A and B in parathyroid tissue of cases of primary hyperparathyroidism: an immunohistochemical study.
        Virchows Arch A Pathol Anat Histopathol. 1991; 418: 295-299
        • Ordóñez N.G.
        Value of GATA3 immunostaining in the diagnosis of parathyroid tumors.
        Appl Immunohistochem Mol Morphol. 2014; 22: 756-761
        • Takada N.
        • Hirokawa M.
        • Suzuki A.
        • et al.
        Diagnostic value of GATA-3 in cytological identification of parathyroid tissues.
        Endocr J. 2016; 63: 621-626
        • Erickson L.A.
        • Mete O.
        Immunohistochemistry in Diagnostic Parathyroid Pathology.
        Endocr Pathol. 2018; 29: 113-129
        • Cameselle-Teijeiro J.M.
        • Eloy C.
        • Sobrinho-Simões
        • et al.
        Challenging Thyroid Tumors: Emphasis on Differential Diagnosis and Ancillary Biomarkers.
        Endocr Pathol. 2020; 31: 197-217
        • Cimino-Mathews A.
        • Sharma R.
        • Netto G.J.
        Diagnostic use of PAX8, CAIX, TTF-1, and TGB in metastatic renal cell carcinoma of the thyroid.
        Am J Surg Pathol. 2011; 35: 757-761
        • Hsi E.D.
        • Zukerberg L.R.
        • Yang W.I.
        • et al.
        Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study.
        J Clin Endocrinol Metab. 1996; 81: 1736-1739
        • Arnold A.
        • Kim H.G.
        • Gaz R.D.
        • et al.
        Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma.
        J Clin Invest. 1989; 83: 2034-2040
        • Costa-Guda J.
        • Arnold A.
        Genetic and epigenetic changes in sporadic endocrine tumors: parathyroid tumors.
        Mol Cell Endocrinol. 2014; 386: 46-54
        • Masi G.
        • Barzon L.
        • Iacobone M.
        • et al.
        Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism.
        Endocrine-Related Cancer. 2008; 15: 1115-1126
        • Woodard G.E.
        • Lin L.
        • Zhang J.H.
        • et al.
        Parafibromin, product of the hyperparathyroidism–jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression.
        Oncogene. 2005; 24: 1272-1276
        • Zhang C.
        • Kong D.
        • Tan M.H.
        • et al.
        Parafibromin inhibits cancer cell growth and causes G1 phase arrest.
        Biochem Biophys Res Commun. 2006; 350: 17-24
        • Yart A.
        • Gstaiger M.
        • Wirbelauer C.
        • et al.
        The HRPT2 tumor suppressor gene promin associated with human PAF1 and RNA polymerase II.
        Mol Cell Biol. 2005; 25: 5052-5060
        • Caroling T.
        • Udelsman R.
        Parathyroid surgery in familial hyperparathyroid disorders.
        J Intern Med. 2005; 257: 27-37
        • Bradley K.J.
        • Hobbs M.R.
        • Buley I.D.
        • et al.
        Uterin tumors are a phenotypic manifestation of the hyerparathyroidism-jaw tumor syndrome.
        J Intern Med. 2005; 257: 18-26
        • Teh B.T.
        • Farnebo F.
        • Kristoffersson U.
        • et al.
        Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas.
        J Clin Endocrinol Metab. 1996; 81: 4204-4211
        • Gill A.J.
        • Lim G.
        • Cheung V.
        • et al.
        Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features.
        Am J Surg Pathol. 2019; 43: 35-46
        • Cetani F.
        • Banti C.
        • Pardi E.
        • et al.
        CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.
        Endocr Connections. 2013; 2: 186-195
        • Carpten J.D.
        • Robbins C.M.
        • Villablanca A.
        • et al.
        HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome.
        Nat Genet. 2002; 32: 676-680
        • Kruijff S.
        • Sidhu S.B.
        • Sywak M.S.
        • et al.
        Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas.
        Ann Surg Oncol. 2014 Feb; 21: 426-433
        • Pyo J.S.
        • Cho W.J.
        Diagnostic and prognostic implications of parafibromin immunohistochemistry in parathyroid carcinoma.
        Biosci Rep. 2019; 39 (BSR20181778)
        • Wei C.H.
        • Harari A.
        Parathyroid carcinoma: update and guidelines for management.
        Curr Treat Options Oncol. 2012; 13: 11-23
        • Schulte J.J.
        • Pease G.
        • Taxy J.B.
        • et al.
        Distinguishing parathyromatosis, atypical parathyroid adenomas, and parathyroid carcinomas utilizing histologic and clinical features.
        Head Neck Pathol. 2021; 15: 727-736
        • Hirokawa M.
        • Suzuki A.
        • Higuchi M.
        • et al.
        Histological alterations following fine-needle aspiration for parathyroid adenoma: incidnce and diagnostic problems.
        Pathol Int. 2021; 71: 400-405
        • Hosny Mohammed K.
        • Siddiqui M.T.
        • Willis B.C.
        • et al.
        Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas from Adenomas.
        Appl Immunohistochem Mol Morphol. 2017; 25: 731-735
        • Gill A.J.
        • Clarkson A.
        • Gimm O.
        • et al.
        Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
        Am J Surg Pathol. 2006; 30: 1140-1149
        • Abbona G.C.
        • Papotti M.
        • Gasparri G.
        • et al.
        Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining.
        Hum Pathol. 1995; 26: 135-138
        • Lloyd R.V.
        • Carney J.A.
        • Ferreiro J.A.
        • et al.
        Immunohistochemical Analysis of the Cell Cycle-Associated Antigens Ki-67 and Retinoblastoma Protein in Parathyroid Carcinomas and Adenomas.
        Endocr Pathol. 1995; 6: 279-287
        • Erovic B.M.
        • Harris L.
        • Jamali M.
        • et al.
        Biomarkers of parathyroid carcinoma.
        Endocr Pathol. 2012; 23: 221-231
        • Bergero N.
        • De Pompa R.
        • Sacerdote C.
        • et al.
        Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases.
        Hum Pathol. 2005 Aug; 36: 908-914
        • Howell V.M.
        • Gill A.
        • Clarkson A.
        • et al.
        Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
        J Clin Endocrinol Metab. 2009; 94: 434-441
        • Osawa N.
        • Onoda N.
        • Kawajiri H.
        • et al.
        Diagnosis of parathyroid carcinoma using immunohistochemical staining against hTERT.
        Int J Mol Med. 2009; 24: 733-741
        • Guarnieri V.
        • Battista C.
        • Muscarella L.A.
        • et al.
        CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.
        Cell Oncol. 2012; 35: 411-422
        • Kutahyalioglu M.
        • Nguyen H.T.
        • Kwatampora L.
        • et al.
        Genetic profiling as a clinical tool in advanced parathyroid carcinoma.
        J Cancer Res Clin Oncol. 2019; 145: 1977-1986
        • Kang H.
        • Pettinga D.
        • Schubert A.D.
        • et al.
        Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
        Oncologist. 2019; 24: 791-797